Nationwide implementation of adjunctive dexamethasone therapy for pneumococcal meningitis
Authors:
- 26 October 2010
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 75 (17) , 1533-1539
Abstract
Background: In this nationwide prospective cohort study, we evaluated the implementation of adjunctive dexamethasone therapy in Dutch adults with pneumococcal meningitis. Methods: From March 2006 through January 2009, all Dutch patients over 16 years old with community-acquired pneumococcal meningitis were prospectively evaluated. Outcome was classified as unfavorable (defined by a Glasgow Outcome Scale score of 1 to 4 points at discharge) or favorable (a score of 5). Clinical characteristics and outcome were compared with a similar nationwide cohort of 352 patients with pneumococcal meningitis from a previous period before guidelines recommended dexamethasone therapy (1998–2002). A multivariable prognostic model was used to adjust for differences in case mix between the 2 cohorts. Results: We evaluated 357 episodes with pneumococcal meningitis in 2006–2009. Characteristics on admission were comparable with the earlier cohort (1998–2002). Dexamethasone was started with or before the first dose of antibiotics in 84% of episodes in 2006–2009 and 3% in 1998–2002. At discharge, unfavorable outcome was present in 39% in 2006–2009 and 50% in 1998–2002 (odds ratio [OR] 0.63; 95% confidence interval [CI] 0.46–0.86; p = 0.002). Rates of death (20% vs 30%; p = 0.001) and hearing loss (12% vs 22%; p = 0.001) were lower in 2006–2009. Differences in outcome remained after adjusting for differences in case mix between cohorts. Conclusions: Dexamethasone therapy has been implemented on a large scale as adjunctive treatment of adults with pneumococcal meningitis in the Netherlands. The prognosis of pneumococcal meningitis on a national level has substantially improved after the introduction of adjunctive dexamethasone therapy. Classification of evidence: This study provides Class III evidence that dexamethasone (10 mg IV, given every 6 hours for 4 days started before or with the first dose of parenteral antibiotics) reduced the proportion of patients with unfavorable outcomes (Glasgow Outcome Scale score of 1 to 4) in the 2006–2009 cohort, as compared to the 1998–2002 cohort (39% vs 50%; OR 0.63; 95% CI 0.46–0.86; p = 0.002). Mortality rate (20% vs 30%; absolute risk difference 10%; 95% CI 4%–17%; p = 0.001) was also lower in 2006–2009.Keywords
This publication has 22 references indexed in Scilit:
- Adjunctive dexamethasone in bacterial meningitis: a meta-analysis of individual patient dataThe Lancet Neurology, 2010
- EFNS guideline on the management of community‐acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adultsEuropean Journal of Neurology, 2008
- Observational Research, Randomised Trials, and Two Views of Medical SciencePLOS Medicine, 2008
- Streptococcus suis Meningitis in Adults in VietnamClinical Infectious Diseases, 2008
- Adjuvant Glycerol and/or Dexamethasone to Improve the Outcomes of Childhood Bacterial Meningitis: A Prospective, Randomized, Double-Blind, Placebo-Controlled TrialClinical Infectious Diseases, 2007
- The Immunopathogenesis of Sepsis in Elderly PatientsClinical Infectious Diseases, 2005
- Practice Guidelines for the Management of Bacterial MeningitisClinical Infectious Diseases, 2004
- Effects of Ampicillin and Corticosteroids on Brain Water Content, Cerebrospinal Fluid Pressure, and Cerebrospinal Fluid Lactate Levels in Experimental Pneumococcal MeningitisThe Journal of Infectious Diseases, 1985
- The need for randomization in the study of intended effectsStatistics in Medicine, 1983
- Cerebrospinal fluid outflow resistance in rabbits with experimental meningitis. Alterations with penicillin and methylprednisolone.Journal of Clinical Investigation, 1980